NCT02193256View on ClinicalTrials.gov

Varenicline + Prazosin for Heavy Drinking Smokers

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

June 30, 2015

Conditions
Cigarette SmokingAlcohol Use Disorders
Interventions
DRUG

Varenicline

Titrated over 1 week to a maximum dose of 2mg/day

DRUG

Prazosin

Titrated over 3 weeks to a maximum dose of 8mg/day

DRUG

Placebo

Trial Locations (1)

06511

Yale University School of Medicine, New Haven

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Yale University

OTHER

NCT02193256 - Varenicline + Prazosin for Heavy Drinking Smokers | Biotech Hunter | Biotech Hunter